TLN-121 for relapsed or refractory lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an investigational drug (TLN-121) for people with certain types of lymphoma that have come back or stopped responding to previous treatments. It aims to see if the drug can control the cancer and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have measurable disease (tumor that can be measured).
- Diagnosis must be one of the specified lymphoma types (e.g., DLBCL, FL grade 3b, transformed FL, or certain T-cell lymphomas).
- Must have received at least 2 prior lines of therapy (or at least 1 for certain T-cell types).
- Must have good performance status (ECOG 0 or 1).
- No current CNS involvement; if past CNS disease, must be fully treated and recurrence-free for 12 months.
- No stem cell transplant within the last 60 days (autologous) or 90 days (allogeneic).
- No CAR-T or other T-cell therapy within the last 4 weeks.
- No major surgery or severe trauma within the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
This study tests an experimental drug for people with B-cell non-Hodgkin lymphoma (a type of blood cancer) that has come back or hasn't responded to standard treatments. The goal is to see if the drug is safe and can shrink the cancer.
This trial tests a new drug called TR115 against the standard treatment options for people with peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if TR115 can help shrink tumors and improve outcomes.
This trial is testing a combination of two drugs for T-cell lymphoma that has returned after prior treatment. The drugs are belinostat (given as an infusion) plus either azacitidine or pralatrexate. The goal is to see if this combination can help control the lymphoma and for how long.
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
This trial tests a new drug, LTZ-301, in people with non-Hodgkin lymphoma whose cancer has come back or not responded to at least two prior treatments. The main goal is to see if LTZ-301 is safe and how the body handles it.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.